TR201808823T4 - Rekombinant vwf nin uygulanması vasıtasıyla koagülasyon hastalığının tedavisi. - Google Patents

Rekombinant vwf nin uygulanması vasıtasıyla koagülasyon hastalığının tedavisi. Download PDF

Info

Publication number
TR201808823T4
TR201808823T4 TR2018/08823T TR201808823T TR201808823T4 TR 201808823 T4 TR201808823 T4 TR 201808823T4 TR 2018/08823 T TR2018/08823 T TR 2018/08823T TR 201808823 T TR201808823 T TR 201808823T TR 201808823 T4 TR201808823 T4 TR 201808823T4
Authority
TR
Turkey
Prior art keywords
rvwf
fviii
compound
rfviii
stability
Prior art date
Application number
TR2018/08823T
Other languages
English (en)
Turkish (tr)
Inventor
Scheiflinger Friedrich
Turecek Peter
Ewenstein Bruce
Yen Wong Wing
M Suiter Tobias
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Publication of TR201808823T4 publication Critical patent/TR201808823T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TR2018/08823T 2011-06-10 2012-06-11 Rekombinant vwf nin uygulanması vasıtasıyla koagülasyon hastalığının tedavisi. TR201808823T4 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US201161523790P 2011-08-15 2011-08-15

Publications (1)

Publication Number Publication Date
TR201808823T4 true TR201808823T4 (tr) 2018-07-23

Family

ID=46321496

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/08823T TR201808823T4 (tr) 2011-06-10 2012-06-11 Rekombinant vwf nin uygulanması vasıtasıyla koagülasyon hastalığının tedavisi.

Country Status (23)

Country Link
US (3) US9272021B2 (enExample)
EP (3) EP3412305B1 (enExample)
JP (3) JP6347468B2 (enExample)
KR (3) KR102319868B1 (enExample)
CN (3) CN103732244A (enExample)
AR (1) AR086904A1 (enExample)
AU (5) AU2012267458A1 (enExample)
CA (1) CA2838845C (enExample)
DK (3) DK3858375T3 (enExample)
ES (3) ES2976169T3 (enExample)
FI (1) FI3858375T3 (enExample)
HK (1) HK1257436A1 (enExample)
HR (1) HRP20180962T1 (enExample)
HU (1) HUE039317T2 (enExample)
LT (1) LT2717905T (enExample)
MX (2) MX350582B (enExample)
PL (3) PL3858375T3 (enExample)
PT (3) PT2717905T (enExample)
RU (2) RU2628537C2 (enExample)
SG (2) SG10201604684WA (enExample)
SI (1) SI2717905T1 (enExample)
TR (1) TR201808823T4 (enExample)
WO (1) WO2012171031A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103732244A (zh) * 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
EP2796145B1 (en) * 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
CN109804432B (zh) 2016-04-15 2023-07-14 武田药品工业株式会社 提供药代动力学药物给药方案的方法和设备
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
JP7326246B2 (ja) 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
MX2020008294A (es) 2018-02-06 2020-11-18 Ablynx Nv Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina.
CA3094644A1 (en) * 2018-03-21 2019-09-26 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
EA202192140A1 (ru) * 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
JP2022547556A (ja) * 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
CA3169996A1 (en) 2020-02-04 2021-08-12 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
EP4251272A4 (en) * 2020-11-24 2024-10-09 Band Therapeutics, LLC COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLEEDING DISORDERS
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2005322067B8 (en) * 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
PL2167117T3 (pl) * 2007-06-13 2013-01-31 Csl Behring Gmbh Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
EP2244814B1 (en) * 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
EP2349314B1 (en) * 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
US20110072524A1 (en) * 2009-08-04 2011-03-24 Baxter International Inc. Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A
EA202090067A3 (ru) 2010-07-08 2020-07-31 Баксалта Инкорпорейтид Способ получения рекомбинантного adamts13 в культуре клеток
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
CN103732244A (zh) * 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病

Also Published As

Publication number Publication date
WO2012171031A1 (en) 2012-12-13
JP6347468B2 (ja) 2018-06-27
RU2019103386A3 (enExample) 2022-01-24
KR20200091476A (ko) 2020-07-30
CN107412743B (zh) 2021-07-02
PT2717905T (pt) 2018-07-02
HRP20180962T1 (hr) 2018-10-19
EP3858375B1 (en) 2024-03-20
PL2717905T3 (pl) 2018-10-31
EP3412305B1 (en) 2021-01-06
DK2717905T3 (en) 2018-07-02
EP3858375A1 (en) 2021-08-04
DK3858375T3 (da) 2024-04-15
PT3858375T (pt) 2024-04-18
JP2017019788A (ja) 2017-01-26
ES2860450T3 (es) 2021-10-05
NZ618790A (en) 2015-07-31
AU2017206235A1 (en) 2017-08-03
CN103732244A (zh) 2014-04-16
MX2013014543A (es) 2014-06-11
CN108210889A (zh) 2018-06-29
ES2682249T3 (es) 2018-09-19
CA2838845C (en) 2019-08-06
AU2017206235B2 (en) 2019-10-17
FI3858375T3 (fi) 2024-04-17
US20120316116A1 (en) 2012-12-13
AU2012267458A1 (en) 2014-01-09
HK1257436A1 (zh) 2019-10-18
CN107412743A (zh) 2017-12-01
HUE039317T2 (hu) 2018-12-28
SG10202002591QA (en) 2020-05-28
EP2717905A1 (en) 2014-04-16
RU2628537C2 (ru) 2017-08-18
LT2717905T (lt) 2018-10-10
RU2017102679A3 (enExample) 2018-12-19
ES2976169T3 (es) 2024-07-24
RU2680402C2 (ru) 2019-02-21
SI2717905T1 (sl) 2018-09-28
JP6527114B2 (ja) 2019-06-05
AR086904A1 (es) 2014-01-29
KR102319868B1 (ko) 2021-11-01
EP2717905B1 (en) 2018-05-23
RU2017102679A (ru) 2018-12-19
SG10201604684WA (en) 2016-07-28
JP2019048892A (ja) 2019-03-28
MX2020000083A (es) 2020-08-06
KR20190041032A (ko) 2019-04-19
EP3412305A1 (en) 2018-12-12
US20160184403A1 (en) 2016-06-30
AU2020200026A1 (en) 2020-01-30
AU2022201518B2 (en) 2025-07-03
PL3412305T3 (pl) 2021-05-31
DK3412305T3 (da) 2021-03-01
AU2022201518A1 (en) 2022-03-24
JP2014516088A (ja) 2014-07-07
AU2016202299A1 (en) 2016-05-05
BR112013031795A2 (pt) 2016-12-20
MX350582B (es) 2017-09-11
RU2014100107A (ru) 2015-07-20
US20250387455A1 (en) 2025-12-25
PT3412305T (pt) 2021-01-29
CA2838845A1 (en) 2012-12-13
AU2016202299B2 (en) 2017-07-20
KR101969515B1 (ko) 2019-04-16
PL3858375T3 (pl) 2024-05-20
RU2019103386A (ru) 2020-08-07
US9272021B2 (en) 2016-03-01
KR20140039285A (ko) 2014-04-01

Similar Documents

Publication Publication Date Title
ES2860450T3 (es) Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
ES2733220T3 (es) Proteína de fusión de hGH-XTEN y su uso en el tratamiento de la deficiencia de la hormona del crecimiento
JP2015527350A (ja) 第ｖｉｉｉ因子の液体製剤
JP7641327B2 (ja) 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
KR20110071012A (ko) 낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자
JP2014532076A (ja) 第ｖｉｉｉ因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用
ES2751361T3 (es) Factor VIII de la coagulación con inmunogenicidad reducida
JP7326246B2 (ja) 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
US20260014236A1 (en) Activators of coagulation factor x and formulations thereof for treating bleeding disorders
BR112013031795B1 (pt) Uso de fator de von willebrand recombinante (rvwf)
HK40056758A (en) Treatment of coagulation disease by administration of recombinant vwf
HK40056758B (en) Treatment of coagulation disease by administration of recombinant vwf
JP2023514541A (ja) 組換えｖｗｆの投与による重症のフォンヴィレブランド病患者における過多月経の治療
HK40001633A (en) Treatment of coagulation disease by administration of recombinant vwf
HK40001633B (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768B (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768A (en) Treatment of coagulation disease by administration of recombinant vwf